Atherosclerosis therapeutic - Rona Therapeutics
Latest Information Update: 31 Mar 2025
At a glance
- Originator Rona Therapeutics
- Class RNA; Vascular disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Atherosclerosis
Most Recent Events
- 25 Mar 2025 Early research in Atherosclerosis in China (unspecified route) before March 2025 (Rona Therapeutics pipeline, March 2025)